Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (Q34162069)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials |
scientific article |
Statements
1 reference
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials (English)
1 reference
Alzheimer’s Disease Neuroimaging Initiative
1 reference
Lon S Schneider
1 reference
Richard E Kennedy
1 reference
Gary R Cutter
1 reference
1 September 2010
1 reference
1 reference
Identifiers
1 reference